Table of Contents

1 Study Coverage

• 1.1 Orphan Drugs Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Orphan Drugs Market Size Growth Rate by Product
  • 1.4.2 Oncology
  • 1.4.3 Gastrointestinal
  • 1.4.4 Pulmonary
  • 1.4.5 Neurology
  • 1.4.6 Hematology
  • 1.4.7 Cardio-vascular
  • 1.4.8 Metabolic disorders
  • 1.4.9 Endocrinology
  • 1.4.10 Infectious diseases
  • 1.4.11 Others
• 1.5 Market by End User
  • 1.5.1 Global Orphan Drugs Market Size Growth Rate by End User
  • 1.5.2 Hospital Pharmacies
  • 1.5.3 Speciality Pharmacies
  • 1.5.4 Retail pharmacies
  • 1.5.5 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Orphan Drugs Market Size
  • 2.1.1 Global Orphan Drugs Revenue 2014-2025
  • 2.1.2 Global Orphan Drugs Sales 2014-2025
• 2.2 Orphan Drugs Growth Rate by Regions
  • 2.2.1 Global Orphan Drugs Sales by Regions
  • 2.2.2 Global Orphan Drugs Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Orphan Drugs Sales by Manufacturers
  • 3.1.1 Orphan Drugs Sales by Manufacturers
  • 3.1.2 Orphan Drugs Sales Market Share by Manufacturers
  • 3.1.3 Global Orphan Drugs Market Concentration Ratio (CR5 and HHI)
• 3.2 Orphan Drugs Revenue by Manufacturers
  • 3.2.1 Orphan Drugs Revenue by Manufacturers (2014-2019)
  • 3.2.2 Orphan Drugs Revenue Share by Manufacturers (2014-2019)
• 3.3 Orphan Drugs Price by Manufacturers
• 3.4 Orphan Drugs Manufacturing Base Distribution, Product Types
  • 3.4.1 Orphan Drugs Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Orphan Drugs Product Type
  • 3.4.3 Date of International Manufacturers Enter into Orphan Drugs Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Orphan Drugs Sales by Product
• 4.2 Global Orphan Drugs Revenue by Product
• 4.3 Orphan Drugs Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Orphan Drugs Breakdown Data by End User

6 North America

• 6.1 North America Orphan Drugs by Countries
  • 6.1.1 North America Orphan Drugs Sales by Countries
  • 6.1.2 North America Orphan Drugs Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Orphan Drugs by Product
• 6.3 North America Orphan Drugs by End User

7 Europe

• 7.1 Europe Orphan Drugs by Countries
  • 7.1.1 Europe Orphan Drugs Sales by Countries
  • 7.1.2 Europe Orphan Drugs Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Orphan Drugs by Product
• 7.3 Europe Orphan Drugs by End User

8 Asia Pacific

• 8.1 Asia Pacific Orphan Drugs by Countries
  • 8.1.1 Asia Pacific Orphan Drugs Sales by Countries
  • 8.1.2 Asia Pacific Orphan Drugs Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Orphan Drugs by Product
• 8.3 Asia Pacific Orphan Drugs by End User

9 Central & South America

• 9.1 Central & South America Orphan Drugs by Countries
  • 9.1.1 Central & South America Orphan Drugs Sales by Countries
  • 9.1.2 Central & South America Orphan Drugs Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Orphan Drugs by Product
• 9.3 Central & South America Orphan Drugs by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Orphan Drugs by Countries
  • 10.1.1 Middle East and Africa Orphan Drugs Sales by Countries
  • 10.1.2 Middle East and Africa Orphan Drugs Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Orphan Drugs by Product
• 10.3 Middle East and Africa Orphan Drugs by End User

11 Company Profiles

• 11.1 Novartis
  • 11.1.1 Novartis Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Novartis Orphan Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Novartis Orphan Drugs Products Offered
  • 11.1.5 Novartis Recent Development
• 11.2 Bristol-Myers Squibb
  • 11.2.1 Bristol-Myers Squibb Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Bristol-Myers Squibb Orphan Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Bristol-Myers Squibb Orphan Drugs Products Offered
  • 11.2.5 Bristol-Myers Squibb Recent Development
• 11.3 Celgene
  • 11.3.1 Celgene Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Celgene Orphan Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Celgene Orphan Drugs Products Offered
  • 11.3.5 Celgene Recent Development
• 11.4 Roche
  • 11.4.1 Roche Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Roche Orphan Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Roche Orphan Drugs Products Offered
  • 11.4.5 Roche Recent Development
• 11.5 Pfizer
  • 11.5.1 Pfizer Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Pfizer Orphan Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Pfizer Orphan Drugs Products Offered
  • 11.5.5 Pfizer Recent Development
• 11.6 Sanofi
  • 11.6.1 Sanofi Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Sanofi Orphan Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Sanofi Orphan Drugs Products Offered
  • 11.6.5 Sanofi Recent Development
• 11.7 Alexion Pharmaceuticals
  • 11.7.1 Alexion Pharmaceuticals Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Alexion Pharmaceuticals Orphan Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Alexion Pharmaceuticals Orphan Drugs Products Offered
  • 11.7.5 Alexion Pharmaceuticals Recent Development
• 11.8 Eli Lilly
  • 11.8.1 Eli Lilly Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Eli Lilly Orphan Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Eli Lilly Orphan Drugs Products Offered
  • 11.8.5 Eli Lilly Recent Development
• 11.9 Novo Nordisk
  • 11.9.1 Novo Nordisk Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Novo Nordisk Orphan Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Novo Nordisk Orphan Drugs Products Offered
  • 11.9.5 Novo Nordisk Recent Development
• 11.10 AstraZeneca
  • 11.10.1 AstraZeneca Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 AstraZeneca Orphan Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 AstraZeneca Orphan Drugs Products Offered
  • 11.10.5 AstraZeneca Recent Development
• 11.11 Eisai
• 11.12 Daiichi Sankyo
• 11.13 Bayer
• 11.14 GlaxoSmithKline
• 11.15 Merck
• 11.16 Johnson & Johnson
• 11.17 Biogen
• 11.18 Shire
• 11.19 Amgen

12 Future Forecast

• 12.1 Orphan Drugs Market Forecast by Regions
  • 12.1.1 Global Orphan Drugs Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Orphan Drugs Revenue Forecast by Regions 2019-2025
• 12.2 Orphan Drugs Market Forecast by Product
  • 12.2.1 Global Orphan Drugs Sales Forecast by Product 2019-2025
  • 12.2.2 Global Orphan Drugs Revenue Forecast by Product 2019-2025
• 12.3 Orphan Drugs Market Forecast by End User
• 12.4 North America Orphan Drugs Forecast
• 12.5 Europe Orphan Drugs Forecast
• 12.6 Asia Pacific Orphan Drugs Forecast
• 12.7 Central & South America Orphan Drugs Forecast
• 12.8 Middle East and Africa Orphan Drugs Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Orphan Drugs Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease.
High unmet needs are one of the primary drivers of market growth. The need for the development of effective drugs with lesser side-effects is rapidly rising in the market.
Moreover, the initiatives from the governments of various countries across the globe towards R&D activities and numerous marketing approvals of these drugs have also influenced the orphan drugs market growth. Furthermore, the rising occurrences of rare diseases with the mounting awareness among the population and larger life expectancy numbers have accelerated the global orphan drug market to grow higher.
The global Orphan Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Orphan Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Orphan Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Orphan Drugs in these regions.
This research report categorizes the global Orphan Drugs market by top players/brands, region, type and end user. This report also studies the global Orphan Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Novartis
Bristol-Myers Squibb
Celgene
Roche
Pfizer
Sanofi
Alexion Pharmaceuticals
Eli Lilly
Novo Nordisk
AstraZeneca
Eisai
Daiichi Sankyo
Bayer
GlaxoSmithKline
Merck
Johnson & Johnson
Biogen
Shire
Amgen

Market size by Product
Oncology
Gastrointestinal
Pulmonary
Neurology
Hematology
Cardio-vascular
Metabolic disorders
Endocrinology
Infectious diseases
Others
Market size by End User
Hospital Pharmacies
Speciality Pharmacies
Retail pharmacies
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Orphan Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Orphan Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Orphan Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Orphan Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Orphan Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Orphan Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.